Exelexis slashes workforce by 70%


US biotech firm Exelexis is cutting around 160 jobs (70% of its workforce). The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer (mCRPC).

The job cuts will leave behind just 70 employees, but the firm anticipates that the cost savings will leave it with ‘sufficient cash to support its operations through to the release of top-line results of [a trial of Cometriq in metastatic renal cell carcinoma] next year’.

A glance at Exelexis’ financial results reveals why such drastic cuts are needed. Cometriq is already approved in the US to treat metastatic medullary thyroid cancer, and brought in $6.5 million (£4 million) in revenue in the second quarter of 2014. However, the firm has made overall operating losses of over $55 million in each quarter of the last year, including spending $47–51 million on R&D. With only $87 million in working capital on its balance sheet, cutting staff and any peripheral clinical trial programmes allows the company to continue its most promising trials in the hope of positive results.


Related Content

Monsanto plans 2600 layoffs

12 October 2015 Business

news image

Sales losses prompt agrochemical giant to slash workforce by 12% over the next two years

Dow to cut 2500 jobs in Corning merger

30 June 2016 Business

news image

Firm will close silicones manufacturing plants in North Carolina and Japan as it absorbs former joint venture

Most Commented

New antibiotic picked from nose bacteria

27 July 2016 Research

news image

Discovery suggests human microbiome may be an untapped source of antimicrobial compounds

Perovskite boosts silicon solar cell efficiency

25 November 2015 News and Analysis

news image

Silicon industry will be ‘beating a path to the door’ of inventors, says scientist